Market News AIOpen the app

Larimar Therapeutics will show three posters about its nomlabofusp program at the Ataxia Research Congress.

TrialRead the original at globenewswire.com
Neutral

Larimar will present previously shared study data and new analyses of blood fats and gene activity. With no new patient results or treatment benefit reported, the news does not change its outlook.

LRMR · Larimar Therapeutics, Inc.

AI read · Neutral

The AI's read

The added analyses could provide more detail about how nomlabofusp affects participants. But the interim study data were already disclosed, and the announcement reports no new patient results or treatment benefit. It does not change the company's outlook.

Get alerts for LRMR

Follow Larimar Therapeutics, Inc. (LRMR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LRMR
Free on the App Store and Google Play, or on the web.